Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04305054
Title Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

melanoma

Therapies

MK-7684 + Pembrolizumab

Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
The Angeles Clinic and Research Institute ( Site 2009) Recruiting Los Angeles California 90025 United States Details
UCLA Hematology & Oncology ( Site 2004) Recruiting Los Angeles California 90095 United States Details
Providence Saint John's Health Center ( Site 2010) Recruiting Santa Monica California 90404 United States Details
University of Colorado, Anschutz Cancer Pavilion ( Site 2012) Recruiting Aurora Colorado 80045 United States Details
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 2022) Recruiting Baltimore Maryland 21231 United States Details
NYU Clinical Cancer Center ( Site 2002) Recruiting New York New York 10016 United States Details
Duke Cancer Institute ( Site 2005) Recruiting Durham North Carolina 27710 United States Details
Oregon Health & Science University ( Site 2013) Completed Portland Oregon 97239 United States Details
University of Pennsylvania Abramson Cancer Center ( Site 2008) Recruiting Philadelphia Pennsylvania 19104 United States Details
West Cancer Center - East Campus ( Site 2014) Recruiting Germantown Tennessee 38138 United States Details
Inova Schar Cancer Institute ( Site 2011) Recruiting Fairfax Virginia 22031 United States Details
Calvary Mater Newcastle-Medical Oncology ( Site 2404) Recruiting Waratah New South Wales 2298 Australia Details
Melanoma Institute Australia ( Site 2402) Recruiting Wollstonecraft New South Wales 2065 Australia Details
Tasman Oncology Research Pty Ltd ( Site 2403) Suspended Southport Queensland 4120 Australia Details
Fiona Stanley Hospital ( Site 2401) Recruiting Murdoch Western Australia 6150 Australia Details
Hopital La Timone ( Site 2103) Recruiting Marseille Bouches-du-Rhone 13005 France Details
C.H. Lyon Sud ( Site 2102) Recruiting Pierre Benite Rhone 69495 France Details
Gustave Roussy ( Site 2101) Recruiting Villejuif Val-de-Marne 94805 France Details
A.P.H. Paris, Hopital Saint Louis ( Site 2107) Recruiting Paris 75010 France Details
HaEmek Medical Center ( Site 2703) Recruiting Afula 1834111 Israel Details
Rambam Health Care Campus-Oncology ( Site 2704) Recruiting Haifa 3109601 Israel Details
Hadassah Ein Karem Jerusalem ( Site 2702) Recruiting Jerusalem 9112001 Israel Details
Chaim Sheba Medical Center ( Site 2701) Recruiting Ramat Gan 5265601 Israel Details
Istituto Oncologico Veneto IRCCS ( Site 2355) Recruiting Padova Veneto 35128 Italy Details
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 2399) Recruiting Milano 20133 Italy Details
Istituto Europeo di Oncologia ( Site 2301) Recruiting Milano 20141 Italy Details
Istituto Nazionale Tumori Fondazione Pascale ( Site 2302) Recruiting Napoli 80131 Italy Details
Policlinico Le Scotte - A.O. Senese ( Site 2377) Recruiting Siena 53100 Italy Details
CHUV Centre Hospitalier Universitaire Vaudois ( Site 2602) Recruiting Lausanne Vaud 1011 Switzerland Details
Universitaetsspital Zuerich ( Site 2601) Recruiting Zuerich Flughafen Zurich 8058 Switzerland Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field